UroGen Pharma

(NASDAQ) URGN

Current Price$28.31

Market Cap$1.40B

Since IPO (2017)+105%

5 Year+63%

1 Year+608%

1 Month+19%

UroGen Pharma Financials at a Glance

Market Cap

$1.40B

Revenue (TTM)

$140.49M

Net Income (TTM)

-$133.23M

EPS (TTM)

-$2.76

P/E Ratio

-10.41

Dividend

$0.00

Beta (Volatility)

1.00 (Low)

Dividend

$0.00

Beta (Volatility)

1.00 (Low)

Price

$28.31

Volume

312,053.661

Open

$28.47

Price

$28.31

Volume

312,053.661

Open

$28.47

Previous Close

$28.69

Daily Range

$27.54 - $28.82

52-Week Range

$3.61 - $32.37

Dividend

$0.00

Beta (Volatility)

1.00 (Low)

Price

$28.31

Volume

312,053.661

Open

$28.47

Previous Close

$28.69

Daily Range

$27.54 - $28.82

52-Week Range

$3.61 - $32.37

URGN News

What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge

Jonathan PoncianoMay 23, 2026

Page 1

URGN: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About UroGen Pharma

Industry

Biotechnology

Sector

Health Care

Employees

291

CEO

Elizabeth Barrett, MBA

Website

www.urogen.com

Headquarters

Princeton, NJ 08540, US

URGN Financials

Key Financial Metrics (TTM)

Gross Margin

90%

Operating Margin

-77%

Net Income Margin

-95%

Return on Equity

Return on Capital

-53%

Return on Assets

-53%

Earnings Yield

-9.61%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.40B

Shares Outstanding

48.72M

Volume

312.05K

Avg. Volume

868.90K

Financials (TTM)

Gross Profit

$97.34M

Operating Income

-$124.86M

EBITDA

-$135.66M

Operating Cash Flow

-$162.44M

Capital Expenditure

-$289.00K

Free Cash Flow

-$162.73M

Cash & ST Invst.

$120.46M

Total Debt

$128.33M

UroGen Pharma Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$50.96M

+151.6%

Gross Profit

$46.82M

+161.2%

Gross Margin

91.88%

N/A

Market Cap

$1.40B

N/A

Market Cap/Employee

$5.97M

N/A

Employees

234

N/A

Net Income

-$23.57M

+46.2%

EBITDA

-$19.61M

+49.6%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

-$55.49M

-178.2%

Accounts Receivable

$55.41M

+182.2%

Inventory

$20.92M

+175.6%

Long Term Debt

$195.18M

+56.2%

Short Term Debt

$1.92M

N/A

Return on Assets

-52.51%

N/A

Return on Invested Capital

-53.29%

N/A

Free Cash Flow

-$45.37M

-7.8%

Operating Cash Flow

-$45.32M

-7.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

NRIXNurix Therapeutics, Inc.

NRIXNurix Therapeutics, Inc.$17.88+1.19%

OCSOculis Holding AG

OCSOculis Holding AG$29.10-1.85%

XNCRXencor, Inc.

XNCRXencor, Inc.$11.93-0.36%

KODKodiak Sciences Inc.

KODKodiak Sciences Inc.$37.42+3.60%

PHATPhathom Pharmaceuticals, Inc.

PHATPhathom Pharmaceuticals, Inc.$9.78-5.23%

BBOTBridgeBio Oncology Therapeutics Inc.

BBOTBridgeBio Oncology Therapeutics Inc.$8.79-0.57%

PROKProKidney Corp.

PROKProKidney Corp.$1.85+2.21%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$16.17-0.01%

REPLReplimune Group

REPLReplimune Group$8.29+0.77%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$38.02-0.01%

NOWLGraniteShares ETF Trust - GraniteShares 2x Long Now Daily ETF

NOWLGraniteShares ETF Trust - GraniteShares 2x Long Now Daily ETF$7.24+0.28%

SMCISuper Micro Computer

SMCISuper Micro Computer$45.74+0.11%

SOFISoFi Technologies

SOFISoFi Technologies$18.42+0.09%

NVDANvidia

NVDANvidia$216.89+0.01%

Questions About URGN

What is the current price of UroGen Pharma?

UroGen Pharma is trading at $28.27 per share.

What is the 52-week range for UroGen Pharma?

Over the past 52 weeks, UroGen Pharma has traded between $3.61 and $32.37.

How much debt does UroGen Pharma have?

As of the most recent reporting period, UroGen Pharma reported total debt of $197.09M.

How much cash does UroGen Pharma have on hand?

UroGen Pharma reported $111.30M in cash and cash equivalents in its most recent financial results.

What is UroGen Pharma’s dividend yield?

UroGen Pharma does not currently have a dividend yield.

UroGen Pharma

UroGen Pharma Financials at a Glance

URGN News

What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge

Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally

UroGen (URGN) Q2 Revenue Rises 11%

Why Shares of UroGen Pharma Jumped Friday

Are These 3 Beaten-Down Biotech Stocks Bargains Now?

Are the Shorts Right About This Clinical-Stage Pharma?

3 Stocks the World's Best Investors Are Buying Right Now

Here's Why the Best Is Yet to Come for UroGen Pharma

URGN: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About UroGen Pharma

URGN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

UroGen Pharma Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About URGN

What is the current price of UroGen Pharma?

What is the 52-week range for UroGen Pharma?

How much debt does UroGen Pharma have?

How much cash does UroGen Pharma have on hand?

What is UroGen Pharma’s dividend yield?

Premium Investing Services